Given Imaging's M2A to be Reimbursed by the Regence Group

11/18/2002 - ATLANTA, GA - Given Imaging, Inc. (NASDAQ: GIVN) announced today that The Regence Group has initiated reimbursement coverage of capsule endoscopy for the small intestine. Regence, through its Blue Cross and Blue Shield affiliates in Oregon, Washington, Utah and Idaho provide healthcare coverage to more than 3 million members. Regence will offer capsule endoscopy reimbursement to those among its beneficiaries who may suffer from disorders associated with gastrointestinal bleeding from sources unidentified by other diagnostic methods. This brings to 38 million the total number of patients in the United States who currently have reimbursable access to the M2A diagnostic system for these indications.

This press release contains forward-looking statements, including projections about our business, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," "intends" and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.Sept.'03